Growth Factors and Angiogenesis in Breast Cancer
An overview of adjuvant therapy in breast cancer has shown the long-term survival benefits in node-positive and-negative cases  (reprinted in part in this volume). However, these treatments have still made only a relatively small impact on mortality, i.e. an increase in 10-year survival from 45% to 51.3% overall and from 39.8% to 46.6% in node-positive cases. Thus, the majority still die from their cancer. Greater understanding of the mechanisms of tumour growth and metastasis may enable the rational development of new agents to complement the achievements of hormone and chemotherapy.
KeywordsBreast Cancer Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Status Imperial Cancer Research Fund Vascular Count
Unable to display preview. Download preview PDF.
- 1.Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71–85Google Scholar
- 6.Nicholson S, Sainsbury RC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL (1991) Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150PubMedCrossRefGoogle Scholar
- 10.Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID (1988) Mitomycin C resistance under aerobic but not hypoxic conditions in a mammalian cell line: association with impaired drug activation and decreased NADPH: cytochrome P-450 reductase activity. Cancer Res 50:775–778Google Scholar
- 13.Philip P, Harris AL, Rea D, Carmichael J, Rajagopalan B, Bedford P, Thompson C, Radda GK (1992) Phase I/II trial of left shifting agent BW12C and mitomycin C. Monitoring by magnetic resonance spectroscopy (MRS). Proc ASCO II:137Google Scholar
- 14.Review Issue (1991) Cell 64:235–364Google Scholar
- 18.Kawada M, Imoto M, Umezawa K (1991) Suppression of multidrug resistance by inostamycin in cultured human carcinoma KB cells. J Cell Pharmacol 2:138–142Google Scholar
- 22.Rea D, Prendiville J, Harris AL, Wolf P, Philip P, Carmichael J, Lewis C, Dallman M, Walker T, Sri-Pathmanathan R, Thatcher N, Crowther D (1992) A phase I study of bryostatin 1 - a protein kinase C partial agonist. EORTC-NIH, New Drugs Conference, AmsterdamGoogle Scholar